• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CEO CORNER
    • SCIENTIFIC ADVISORY BOARD
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Akari TX

Akari TX / January 30, 2014

Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ

NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX)(formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the …

[Read more...] about Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ

Akari TX / October 24, 2013

Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer

NEW YORK AND LONDON Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo …

[Read more...] about Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer

Akari TX / October 24, 2013

Celsus Therapeutics Names Allan Shaw to Board of Directors

NEW YORK AND LONDON Celsus Therapeutics(OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of …

[Read more...] about Celsus Therapeutics Names Allan Shaw to Board of Directors

Akari TX / October 21, 2013

Celsus Therapeutics MRX-6 Selected as One of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence

NEW YORK AND LONDON Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company MRX-6 …

[Read more...] about Celsus Therapeutics MRX-6 Selected as One of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence

« Previous Page

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.